News
NRSN
0.7100
-0.11%
-0.0008
Weekly Report: what happened at NRSN last week (0406-0410)?
Weekly Report · 1d ago
NeuroSense Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones · 6d ago
NeuroSense Therapeutics Price Target Maintained With a $14.00/Share by D. Boral Capital
Dow Jones · 6d ago
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Opus Genetics (IRD)
TipRanks · 04/07 13:40
NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC
TipRanks · 04/06 13:56
NeuroSense Therapeutics Granted Patent From Brazilian Patent And Trademark Office Entitled 'Compositions Comprising Ciprofloxacin And Celecoxib'
Benzinga · 04/06 13:21
NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042
Reuters · 04/06 13:20
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
PR Newswire · 04/06 13:20
Weekly Report: what happened at NRSN last week (0330-0403)?
Weekly Report · 04/06 09:56
Reported Friday, NeuroSense Therapeutics Receives Dual Nasdaq Non-Compliance Notices For Minimum Bid Price And $35M Market Value Requirements, Given Until September 29, 2026
Benzinga · 04/06 07:19
NeuroSense Therapeutics receives Nasdaq notices over listing requirements
Seeking Alpha · 04/03 14:54
NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement
Reuters · 04/03 14:03
NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status
TipRanks · 04/03 13:47
Neurosense Therapeutics Ltd. (NRSN) Receives a Buy from Roth MKM
TipRanks · 04/02 12:46
NeuroSense files Form 3 as CFO Or Eisenberg reports beneficial ownership
Reuters · 04/01 20:25
Noble Financial Remains a Buy on Neurosense Therapeutics Ltd. (NRSN)
TipRanks · 04/01 13:56
NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial
TipRanks · 03/31 21:22
NeuroSense Therapeutics director Revital Mandil-Levin files initial beneficial ownership statement
Reuters · 03/31 20:28
NeuroSense Therapeutics reports FY results, GAAP EPS of $0.44
Seeking Alpha · 03/31 15:18
Israel's NeuroSense Therapeutics 2025 net loss widens as expenses rise
Reuters · 03/31 13:31
More
Webull provides a variety of real-time NRSN stock news. You can receive the latest news about Neurosense Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NRSN
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease